
Milken Panel
From left: Bertha Coombs, former senior health care reporter, CNBC; Steven C. Anderson, president and CEO, NACDS; Shantanu Agrawal, chief health officer, Elevance Health; and Charles “Chuck” Henderson, CEO, American Diabetes Association, at the Milken Institute 2026 Future of Health Summit
On Friday, NACDS President and CEO Steven C. Anderson joined healthcare leaders at the Milken Institute 2026 Future of Health Summit to discuss how GLP-1 therapies, and the support patients need with them, can reach communities effectively and sustainably.
Anderson shared findings from Beyond the Prescription: Community Pharmacy’s Role in Comprehensive GLP-1 Care, new Milken Institute research supported by NACDS. The report finds that neighborhood pharmacies already perform key elements of GLP-1 care, from side-effect management to adherence support. Pharmacists see people monthly at refill, while other healthcare professionals typically do not, and the most common reasons people stop taking a GLP-1, difficult side effects and affordability issues, frequently surface at the pharmacy counter. The report lays out a roadmap for policymakers, payers, prescribers, pharmacies, and patients, including reimbursement pathways for pharmacist wraparound GLP-1 care.
Patients agree. In opinion research NACDS commissioned to complement the report, 93 percent of GLP-1 users said they are confident in pharmacists as a resource for GLP-1 questions.
Share this story:
Related Posts
Beyond the Prescription: New Milken Institute Report Finds Pharmacies Play a Pivotal Role in GLP-1 Patient Success Over Time, Outlines Path to Make That Role Sustainable
Supported by NACDS, the report outlines recommendations for policymakers, payers, prescribers, pharmacies, and patients, and companion research shows GLP-1 users overwhelmingly see pharmacists as a trusted resource.



